Analysts Conflicted on These Healthcare Names: Globus Medical (NYSE: GMED), Incyte Corp (NASDAQ: INCY) and Celgene (NASDAQ: CELG)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Globus Medical (NYSE: GMED), Incyte Corp (NASDAQ: INCY) and Celgene (NASDAQ: CELG).

Globus Medical (NYSE: GMED)

Oppenheimer analyst Steven Lichtman reiterated a Hold rating on Globus Medical (NYSE: GMED) today. The company’s shares closed yesterday at $31.24, close to its 52-week high of $33.06.

According to TipRanks.com, Lichtman is ranked 0 out of 5 stars with an average return of -4.1% and a 55.0% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Integra Lifesciences.

Globus Medical has an analyst consensus of Moderate Buy, with a price target consensus of $33.50.

Incyte Corp (NASDAQ: INCY)

Oppenheimer analyst Jay Olson reiterated a Hold rating on Incyte Corp (NASDAQ: INCY) today and set a price target of $125. The company’s shares closed yesterday at $120.49.

Olson noted:

“ASCO abstracts yielded data for epacadostat in various tumor types, supporting decisions to move the combo with PD-1 into Ph 3 studies based on efficacy in NSCLC, UC, SCCHN and RCC with safety and tolerability similar to PD-1 monotherapy. Overall, these data confirm the potential utility for epacadostat outside of melanoma and in earlier lines of therapy, which is consistent with INCY’s previous announcement that epacadostat + Keytruda would be studied in the first line setting for NSCLC, UC, SCCHN and RCC. We caution that patient numbers are small in these abstracts and some of the data cuts make cross-trial comparisons even more challenging than usual. Our key questions are outlined below.”

According to TipRanks.com, Olson is a 3-star analyst with an average return of 5.3% and a 62.0% success rate. Olson covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Intercept Pharma, and Axovant Sciences.

Incyte Corp has an analyst consensus of Strong Buy, with a price target consensus of $149.08.

Celgene (NASDAQ: CELG)

Oppenheimer analyst Leah R. Cann reiterated a Buy rating on Celgene (NASDAQ: CELG) today and set a price target of $148. The company’s shares closed yesterday at $117.10.

R. Cann noted:

“Celgene had numerous abstract released by the American Society of Clinical Oncology (ASCO) yesterday. These were supportive of our outlook for Celgene and we are highlighting four in this note. Our estimates for product sales remain unchanged.”

According to TipRanks.com, Cann is a 4-star analyst with an average return of 10.4% and a 68.4% success rate. Cann covers the Healthcare sector, focusing on stocks such as CytomX Therapeutics Inc, Seattle Genetics, and Acceleron Pharma.

Currently, the analyst consensus on Celgene is Strong Buy and the average price target is $147.89, representing a 26.3% upside.

In a report issued on May 12, Jefferies also reiterated a Buy rating on the stock with a $154 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.